Zoledronic acid (ZOL 446)

For research use only.

Catalog No.S1314 Synonyms: Zoledronate, CGP-4244, GP42446A, Zometa, Zomera, Aclasta, Reclast

29 publications

Zoledronic acid (ZOL 446) Chemical Structure

CAS No. 118072-93-8

Zoledronic acid (ZOL 446, ZA, Zoledronate, CGP-4244, GP42446A, Zometa, Zomera, Aclasta, Reclast), a potent osteoclast inhibitor, induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho. Zoledronic acid (ZA) also induces autophagy.

Selleck's Zoledronic acid (ZOL 446) has been cited by 29 publications

Purity & Quality Control

Choose Selective Ras Inhibitors

Biological Activity

Description Zoledronic acid (ZOL 446, ZA, Zoledronate, CGP-4244, GP42446A, Zometa, Zomera, Aclasta, Reclast), a potent osteoclast inhibitor, induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho. Zoledronic acid (ZA) also induces autophagy.
Targets
Rho [1]
(Cell-free assay)
Ras [1]
()
In vitro

Zoledronic acid (10 µM and 100 µM) causes a significant reduction in the proportions of MCF-7 cells (49.54% and 23.55% of control, respectively) (P < 0.05). Zoledronic acid has little effect on MDA-MB-231 cells at concentrations of 0.1–10 µM, whereas the 100 µM concentration results in a significant reduction in cell number. Zoledronic acid (100 µM) results in a 63.5% reduction in MCF-7 cell number at 72 hours and an 87.1% reduction at 96 hours. Zoledronic acid (10 µM) results in a greater than 4-fold increase in MCF-7 cell apoptosis whereas the 100 µM concentration induces a 6-fold increase in the proportion of apoptotic cells. Zoledronic acid (10 µM) and paclitaxel (2 µM) results in a 5-fold increase in apoptosis (774.8% of control) compared to zoledronic acid alone (155.71%) and a 4-fold increase compared to paclitaxel alone (189.68%). Zoledronic acid-induced apoptosis of MCF-7 breast cancer cells can be inhibited by addition of intermediates of the mevalonate pathway, which is consistent with observations in osteoclasts, macrophages and myeloma cells. [1] Zoledronic acid enhances OPG gene expression and protein secretion by human osteoblasts (hOB) in a dose-dependent fashion with a maximum effect at 10 nM after 72 hours, consistent with the higher biological potency of Zoledronic acid. Zoledronic acid prevents the inhibitory effects of the glucocorticoid dexamethasone on OPG mRNA and protein production in human osteoblasts. Zoledronic acid induces type I collagen secretion and alkaline phosphatase activity by 2- and 4-fold, respectively, in human osteoblasts. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human NCI-H460 cell Ml\yVJJwdGmoZYLheIlwdiCjc4PhfS=> NU\VNWhlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxtKGyrbnWgZpkhVVSWIHHzd4F6NCCLQ{WwQVEyNjdizszN MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjl5MESwOUc,OTZ7N{C0NFU9N2F-
human SF-268 cell NH2xSXpRem:uaX\ldoF1cW:wIHHzd4F6 MnrmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVRj2yOlgh[2WubDDsbY5mKGK7IF3UWEBie3OjeTygTWM2OD1zND6zJO69VQ>? NUDPW4FFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5O|A1ODVpPkG2PVcxPDB3PD;hQi=>
Gamma delta T cells MX7GeY5kfGmxbjDhd5NigQ>? NUjG[mJ2TW[oZXP0bZZmKGOxbnPlcpRz[XSrb36gZYdicW6|dDDoeY1idiCJYX3tZUBl\Wy2YTDUJINmdGy|LDDFR|UxRTVwNN88US=> MkLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6Mki4N|QoRjF3OEK4PFM1RC:jPh?=
HFF cells NGDkV45HfW6ldHnvckBie3OjeR?= MXjJckB3cXS{bzDpcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCC2aHWg[5Jwf3SqIH;mJHRwgG:ybHHzcYEh\2:wZHnpJIlvKGi3bXHuJIZwemW|a3nuJIZq[nKxYnzhd5QhdW:wb3zhfYVzKGOnbHzzJEhJTkZiY3XscJMqNCCLQ{WwQVAvPzoQvF2= NUPm[|ZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4OVcyOTlpPkG1PFU4OTF7PD;hQi=>
HFF cells NV7HeVlXTnWwY4Tpc44h[XO|YYm= MV\Jcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCC2aHWg[5Jwf3SqIH;mJHRwgG:ybHHzcYEh\2:wZHnpJI93\XKneIDy[ZN{cW6pIF\QVHMh\W68eX3lJIlvKGi3bXHuJIZwemW|a3nuJIZq[nKxYnzhd5QhdW:wb3zhfYVzKGOnbHzzP{Ap[2:wdILvcEA:KDBwNkCgeW0tKGW6cHXybY1mdnRiMTmsJGlEPTB;Nz64{txO MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh3N{GxPUc,OTV6NUexNVk9N2F-
HFF cells MVvGeY5kfGmxbjDhd5NigQ>? MXnJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCC2aHWg[5Jwf3SqIH;mJHRwgG:ybHHzcYEh\2:wZHnpJI93\XKneIDy[ZN{cW6pIF\QVHMh\W68eX3lJIlvKGi3bXHuJIZwemW|a3nuJIZq[nKxYnzhd5QhdW:wb3zhfYVzKGOnbHzzP{Ap[2:wdILvcEA:KDBwN{mgeW0tKGW6cHXybY1mdnRiMzmsJGlEPTB;Nz64{txO NITDUok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUi1O|EyQSd-MUW4OVcyOTl:L3G+
HFF cells Mof6SpVv[3Srb36gZZN{[Xl? MlLFTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RidHjlJIdzd3e2aDDv[kBVd3ixcHzhd41iKGexbnTpbUBwfmW{ZYjwdoV{e2mwZzDGVHBUKGWweont[UBqdiCqdX3hckBnd3Knc3vpckBncWK{b3LsZZN1KG2xbn;sZZlmeiClZXzsd|shMGOxboTyc4whRSBzLkGgeW0tKGW6cHXybY1mdnRiMjmsJGlEPTB;OD6z{txO M{fuTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OEW3NVE6Lz5zNUi1O|EyQTxxYU6=
BT-549 Ml7FRY51cXS3bX;yJIF{e2G7 M3\mOmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUMVU1QSClZXzsd{B5\W6xZ4Lh[pRm\CCVQ1nEJI1wfXOnIHPvMZRz[W6|ZnXjeIVlKHerdHigbJVu[W5iZ3HtcYEh\GWudHGgWEBtgW2yaH;jfZRmeyCjc4Pld5Nm\CCjczDzeZJ3cX[jbDD0bY1mKHC{b3zvcodifGmxbjDheEAzKHWpLDDpdEBkd2GmbXnubZN1\XKnZDD3bZRpKGi3bXHuJJJm[2:vYnnuZY51KEmOMh?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl|N{SzOEc,OTh7M{e0N|Q9N2F-
BT-549 NGD3e29CdnSrdIXtc5Ih[XO|YYm= NEnkWYNCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCWE02PDliY3XscJMhgGWwb3fyZYZ1\WRiU1PJSEBud3W|ZTDjc{11emGwc3\lZ5Rm\CC5aYToJIh2dWGwIHfhcY1iKGSnbIThJHQhdHmvcHjvZ5l1\XNiYYPz[ZN{\WRiYYOgd5Vzfmm4YXygeIlu\SCycn;sc45o[XSrb36gZZQhPSC3ZzygbZAh[2:jZH3pcol{fGW{ZXSge4l1cCCqdX3hckBz\WOxbXLpcoFvfCCLTEK= M2q2T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUO3OFM1Lz5zOEmzO|Q{PDxxYU6=
BL21(DE3) NE\lTmFHfW6ldHnvckBie3OjeR?= NUjNSXFiOzBibXnudy=> M4PtUmlvcGmkaYTpc44hd2ZiSHnzOk11[WepZXSgbJVu[W5idIL1coNifGWmIF\QVHMhMDZvM{WzLUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxLGRGOyliY3XscJMhfXOrbneg[4Vz[W67bDDkbZBpd3OyaHH0[UBidmRiaYPvdIVvfGWweXyg[IlxcG:|cHjheIUh[XNic4Xid5Rz[XSnIIDy[Ylv[3WkYYTl[EB4cXSqIHXufplu\SCob4KgN|AhdWmwczDifUB{eGWldILvdIhwfG:vZYTybYMh[W6jbInzbZMtKEmFNUC9NE4y|ryP Ml3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUC1PVcoRjJ|NkGwOVk4RC:jPh?=
BL2-codon plus (DE3) RIL NWrtdZo6TnWwY4Tpc44h[XO|YYm= NHeyRXM{OCCvaX7z NYDkT4xJUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqezZvdHHn[4VlKFCuYYPtc4RqfW1idnn2ZZghT0eSUGOg[ZhxemW|c3XkJIlvKEW|Y3jldolkcGmjIHPvcIkhSkx{LXPv[I9vKHCudYOgLGRGOyliUlnMJINmdGy|IIXzbY5oKGencnHufYwh\GmyaH;zdIhifGViYX7kJIl{d3CnboTlcpltKGSrcHjvd5Bp[XSnIHHzJJN2[nO2cnH0[UBxemWrbnP1ZoF1\WRid3n0bEBmdnq7bXWg[o9zKDNyIH3pcpMh[nlic4DlZ5Rzd3Cqb4TvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTBwMUROwG0> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMEW5O{c,OjN4MUC1PVc9N2F-
RPMI8226 MoOyR5l1d3SxeHnjbZR6KGG|c3H5 NHrWfYU4OiCqcoO= NHH6V5NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTWE2LOEKyOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDFR|UxRTFzzszN NFzxdW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m5PFkzOSd-MkO5PVg6OjF:L3G+
J774 M4\OV2N6fG:2b4jpZ4l1gSCjc4PhfS=> M3PtbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGo4PzRiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7LDDJR|UxRTdwON88US=> NVjlNpVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVM4PDJpPkK0PFE{PzR{PD;hQi=>
MCF7 M3nXfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MlLSO|IhcHK| MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0zO87:TR?= MnTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkizPVkoRjJ2OUK4N|k6RC:jPh?=
Vgamma9/Vdelta2 T-cells NHrvS5VHfW6ldHnvckBie3OjeR?= NVHrVWlKOThiaILz MXPCbY5lcW6pIHHm[olvcXS7IITvJIJ2fHm{b4DobYxqdiB|QUGgbY4hcHWvYX6gWodidW2jOT;W[IVtfGF{IGStZ4VtdHNiYYPz[ZN{\WRiYYOgZYN1cX[jdHnvckBw\iCYZ3HtcYE6N1[mZXz0ZVIhXC2lZXzsd{BjgSC3cILl[5Vt[XSrb36gc4YhS0R4OTDhcoQhS0R{NTDh[pRmeiBzODDodpMtKEWFNUC9NE41QDZ4zszN NVHBe5N[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVc5QThpPkK5OFU4QDl6PD;hQi=>
RPMI8226 NEG1bXRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NXrYW4xkPzJiaILz Mmi4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUUF3JPFIzPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBGSzVyPUGx{txO NVrXe|ZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNVYxQTFpPkOwNFE3ODlzPD;hQi=>
RPMI8226 NEfxUllHfW6ldHnvckBie3OjeR?= NFrzZWQxNjVidV2= NX7ReoZlUW6qaXLpeIlwdiCxZjDHS3BRWyCrbjDoeY1idiCUUF3JPFIzPiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gVoFxOUFicILlcplt[XSrb36gZZQhOC53IIXNJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MoLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByMU[wPVEoRjNyMEG2NFkyRC:jPh?=
J774A.1 MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NYO3V3ptOTByIIXN NV7zRlBYPzJiaILz MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEp5N{TBMlEh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEGwNEB2VSCjZoTldkA4OiCqcoOgZpkhX1OWODDhd5NigQ>? NHO1PYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEKxOlg2OSd-M{CyNVY5PTF:L3G+
RAW264.7 Mn2yRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NEXpb2oyODBidV2= NH;zZ2c4OiCqcoO= MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCxNFAhfU1iYX\0[ZIhPzJiaILzJIJ6KFeVVEigZZN{[Xl? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJzNki1NUc,OzB{MU[4OVE9N2F-
MG63 MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M1q1SVExOCC3TR?= M1;Pe|czKGi{cx?= NGnDeHlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3HOlMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEGwNEB2VSCjZoTldkA4OiCqcoOgZpkhX1OWODDhd5NigQ>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJzNki1NUc,OzB{MU[4OVE9N2F-
PC3 MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MYSxNFAhfU1? NWj5PVZzPzJiaILz NXuwdFM6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEGwNEB2VSCjZoTldkA4OiCqcoOgZpkhX1OWODDhd5NigQ>? MmriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MU[4OVEoRjNyMkG2PFUyRC:jPh?=
RAW264.7 MYnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHvWVI8yODBidV2= NEDIXGk4OiCqcoO= MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGLBUmtNNWSrZn\ldoVvfGmjdHXkJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEAyODBidV2gZYZ1\XJiN{KgbJJ{KGK7IFPDT|gh[XO|YYm= M3HIclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkG2PFUyLz5|MEKxOlg2OTxxYU6=
RAW264.7 MmH1SpVv[3Srb36gZZN{[Xl? NU\Dd5BSPzJiaILz NF\K[HdKdmirYnn0bY9vKG:oIGLBUmtNNWmwZIXj[YQhd3O2ZX;jcIF{fG:pZX7ld4l{KGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDUVmFRKHO2YXnubY5oKGKjc3XkJI1q[3Kxc3PvdIlkKGGwYXz5d4l{ MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MU[4OVEoRjNyMkG2PFUyRC:jPh?=
MC3T3-E1 NV7VS4hWTnWwY4Tpc44h[XO|YYm= MWGzNEB1dyB3MDDuUS=> M2XURlExKHSxIEG1JIRigXN? NWXPbJNyUW6mdXP0bY9vKG:oIH3pcoVz[WyrenH0bY9vKGmwIH3veZNmKE2FM2SzMWUyKGOnbHzzJIF1KDNyIITvJFUxKG6PIHHmeIVzKDFyIITvJFE2KGSjeYOgZpkh[WyrenHybY4hemWmIHT5[UBj[XOnZDDhd5NigQ>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJzNki1NUc,OzB{MU[4OVE9N2F-
C57BL mouse bone marrow cells NUO4epFDTnWwY4Tpc44h[XO|YYm= M1rNblUxKG6P M3fkN|ExKHSxIEG1JIRigXN? NEfScpJKdmS3Y4Tpc44hd2ZibXnu[ZJidGm8YYTpc44hcW5iQ{W3RmwhdW:3c3WgZo9v\SCvYYLyc5ch[2WubIOgZZQhPTBibl2gd5VxeGynbXXueIVlKHerdHig[pJme2hibXXkbZVuKGOxboThbY5qdmdiY3;tdI92dmRiZY\ldpkhOyCmYYnzJIZweiBzMDD0c{AyPSCmYYnzJIJ6KGGuaYrhdolvKHKnZDDkfYUh[mG|ZXSgZZN{[Xl? M1KzWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkG2PFUyLz5|MEKxOlg2OTxxYU6=
C57BL mouse bone marrow cells/human PC3 cells NFG0NJFHfW6ldHnvckBie3OjeR?= MkXMOVAhfG9iMUCwJI5O NIP0WnYyOCC2bzCxOUBl[Xm| MYfJcoR2[3Srb36gc4YhdWmwZYLhcIl7[XSrb36gbY4hSzV5QlygcY92e2ViYn;u[UBu[XK{b4egZ4VtdHNiY3:tZ5VtfHW{ZXSge4l1cCCqdX3hckBRSzNiY3XscJMh[XRiNUCgeI8hOTByIH7NJJN2eHCuZX3lcpRm\CC5aYToJIZz\XOqIH3l[Il2dSClb370ZYlvcW6pIHPvcZBwfW6mIHX2[ZJ6KDNiZHH5d{Bnd3JiMUCgeI8hOTViZHH5d{BjgSCjbHn6ZZJqdiC{ZXSg[JlmKGKjc3XkJIF{e2G7 MlPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MU[4OVEoRjNyMkG2PFUyRC:jPh?=
K562 MYHGeY5kfGmxbjDhd5NigQ>? M3vUXVI1OCCvaX7z MVjBZ5RqfmG2aX;uJI9nKGK3dInyc5BpcWyrbjCzRVEhcW5iaIXtZY4hUzV4MjDj[YxteyCjc4Pld5Nm\CCjczDpcpRmem[ncn;uMYdidW2jIIDyc4R2[3Srb36gdJJmfHKnYYTl[EBnd3JiMkSwJI1qdnNiZn;scI94\WRiYomgTG1DWFBvdILlZZRm\CCYZ3HtcYE6XmSnbIThNkBVKGOnbHzzJIFl\Gm2aX;uJIFv\CCvZXHzeZJm\CCjZoTldkAzOCCqcoOgZpkhTUyLU1GsJGVEPTB;MkROwG0> M4rURVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNUOxNVk5Lz5|MUWzNVE6QDxxYU6=
MIAPaCa2 M{DzWGN6fG:2b4jpZ4l1gSCjc4PhfS=> NEDXcHc4OiCqcoO= NWO4V5NsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUmDUHHDZVIh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEBoem:5dHigcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygSWM2OD1zMz60{txO MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTd{NUK5O{c,OzF5MkWyPVc9N2F-
PANC1 MUfDfZRwfG:6aXPpeJkh[XO|YYm= MnLjO|IhcHK| NYLDOG5FS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEGQQ{GgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDDndo94fGhibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiRVO1NF0yPi5zzszN MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTd{NUK5O{c,OzF5MkWyPVc9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
ALDH1 / Oct4 / Nanog / Sox2 / CD49f ; 

PubMed: 30791957     


Western blot analysis of ALDH1, Sox2, CD49f, Nanog, and Oct4 in cervical cancer cells derived CSCs treated or not with zoledronic acid (10, 20, and 30 μM).

N-cadherin / E-cadherin / Vimentin ; 

PubMed: 30791957     


Western blot analysis of E-cadherin, N-cadherin, and Vimentin in cervical cancer cells derived CSCs treated or not with zoledronic acid (10, 20, and 30 μM).

30791957
Growth inhibition assay
Cell viability; 

PubMed: 30791957     


Zoledronic acid inhibits the proliferation of cervical cancer cells derived CSCs in vitro. Parental HeLa, SiHa, and CaSki cells as well as their derived CSCs were seeded in 96-well plates and treated with zoledronic acid at different concentrations for 1–5 days. Cell viability was determined by the modified MTT assay. OD values of each treated group were compared with that of the control at the same time point. Control vs. 5, 10, 20, 40, and 80 μM of zoledronic acid: * P < 0.05, ** P < 0.01. Results are shown as mean values ± SD of independent experiments performed in triplicate.

30791957
In vivo Zoledronic acid (120 mg/kg, s.c.) prevents the formation of lesions, prevents cancellous bone loss and loss of bone mineral density, and reduces osteoclast perimeter in 5T2MM-bearing mice. Zoledronic acid (120 mg/kg, s.c.) also decreases paraprotein concentration, decreases tumor burden, and reduces angiogenesis in 5T2MM-bearing mice. [3]

Protocol

Solubility (25°C)

In vitro 0.1M NaOH (aq) 40 mg/mL (147.01 mM)
DMSO 0.004 mg/mL (0.01 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 272.09
Formula

C5H10N2O7P2

CAS No. 118072-93-8
Storage powder
in solvent
Synonyms Zoledronate, CGP-4244, GP42446A, Zometa, Zomera, Aclasta, Reclast
Smiles C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04719481 Not yet recruiting Drug: Pravastatin Sodium 80 MG|Drug: Placebo Postmenopausal Osteoporosis Peking University Third Hospital November 2021 Phase 4
NCT04719650 Not yet recruiting Drug: Zoledronic Acid Injection|Drug: Placebo Postmenopausal Osteoporosis Peking University Third Hospital October 2021 Phase 4
NCT04034199 Unknown status Drug: Denosumab|Drug: Zoledronic Acid Idiopathic Inflammatory Myopathies|Osteoporosis Osteopenia Kwong Wah Hospital|Tung Wah Group of Hospitals August 15 2019 Phase 3
NCT03862833 Recruiting Drug: IL2|Drug: Zoledronic Acid Hematopoietic Stem Cell Transplantation Nantes University Hospital May 7 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo studies?

  • Answer:

    Please dissolve this compound directly to 30% PEG400+0.5% Tween80+5% Propylene glycol.

Ras Signaling Pathway Map

Tags: buy Zoledronic acid (ZOL 446) | Zoledronic acid (ZOL 446) ic50 | Zoledronic acid (ZOL 446) price | Zoledronic acid (ZOL 446) cost | Zoledronic acid (ZOL 446) solubility dmso | Zoledronic acid (ZOL 446) purchase | Zoledronic acid (ZOL 446) manufacturer | Zoledronic acid (ZOL 446) research buy | Zoledronic acid (ZOL 446) order | Zoledronic acid (ZOL 446) mouse | Zoledronic acid (ZOL 446) chemical structure | Zoledronic acid (ZOL 446) mw | Zoledronic acid (ZOL 446) molecular weight | Zoledronic acid (ZOL 446) datasheet | Zoledronic acid (ZOL 446) supplier | Zoledronic acid (ZOL 446) in vitro | Zoledronic acid (ZOL 446) cell line | Zoledronic acid (ZOL 446) concentration | Zoledronic acid (ZOL 446) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID